Vivos Therapeutics (VVOS) Other Operating Expenses (2020 - 2026)

Vivos Therapeutics (VVOS) has reported Other Operating Expenses for 7 consecutive years, with $210000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other Operating Expenses rose 3400.0% year-over-year to $210000.0 in Q2 2026; TTM through Jun 2026 was $990000.0, a 1256.16% increase from a year earlier, with the FY2025 full-year figure at $609000.0, up 651.85% from the prior year.
• Other Operating Expenses was $210000.0 for Q2 2026 at Vivos Therapeutics, up from $154000.0 in the prior quarter.
• Over five years, Other Operating Expenses peaked at $642000.0 in Q4 2025 and troughed at -$131000.0 in Q4 2022.
• A 5-year average of $52444.4 and a median of $25000.0 in 2024 frame the typical range for Other Operating Expenses.
• Across the five-year window, Other Operating Expenses sank 150.0% in 2025 and jumped 3400.0% in 2026, its largest moves.
• Over 5 years, Other Operating Expenses stood at -$131000.0 in 2022, then surged by 61.07% to -$51000.0 in 2023, then soared by 186.27% to $44000.0 in 2024, then surged by 1359.09% to $642000.0 in 2025, then sank by 67.29% to $210000.0 in 2026.
• The last three Other Operating Expenses figures came in at $210000.0 (Q2 2026), $154000.0 (Q1 2026), and $642000.0 (Q4 2025), per Business Quant data.